Is Ipsen S.A.'s (EPA:IPN) Future Growth Already Accounted For In Today's Price?

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

Ipsen S.A. (EPA:IPN) is considered a high growth stock. However its last closing price of €115.8 left investors wondering whether this growth has already been factored into the share price. Let’s take a look at some key metrics to determine whether there's any value here for current and potential future investors.

See our latest analysis for Ipsen

How is IPN going to perform in the future?

Analysts are predicting good growth prospects for Ipsen over the next couple of years. The consensus forecast from 13 analysts is bullish with earnings per share estimated to rise from today's level of €4.674 to €8.223 over the next three years. On average, this leads to a growth rate of 14% each year, which indicates a solid future in the near term.

Can IPN's share price be justified by its earnings growth?

Ipsen is available at price-to-earnings ratio of 24.77x, showing us it is overvalued based on current earnings compared to the Pharmaceuticals industry average of 23.2x , and overvalued compared to the FR market average ratio of 17.78x .

After looking at IPN's value based on current earnings, we can see it seems overvalued relative to other companies in the industry. But, since Ipsen is a high-growth stock, we must also account for its earnings growth by using calculation called the PEG ratio. A PE ratio of 24.77x and expected year-on-year earnings growth of 14% give Ipsen a higher PEG ratio of 1.8x. This tells us that when we include its growth in our analysis Ipsen's stock can be considered a bit overvalued , based on its fundamentals.

What this means for you:

IPN's current overvaluation could signal a potential selling opportunity to reduce your exposure to the stock, or it you're a potential investor, now may not be the right time to buy. However, basing your investment decision off one metric alone is certainly not sufficient. There are many things I have not taken into account in this article and the PEG ratio is very one-dimensional. If you have not done so already, I highly recommend you to complete your research by taking a look at the following:

1. Financial Health: Are IPN’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.
2. Past Track Record: Has IPN been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of IPN's historicals for more clarity.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.